RNA Horizons 2026 Poster Presentations
BOARD NO.
1
A comprehensive platform for well-defined Antibody-Oligonucleotide conjugates
Daniele Addis
Axolabs GmbH, Kulmbach, Germany
2
RBM39 as a therapeutic target in Nasopharyngeal Cancer
Prachi Amuley
Nanyang Technological University, Singapore
3
A Rapid, Cell-Based based High-Throughput Assay for Small Molecule Inhibitors of RBP–RNA Interactions
Jugajyoti Baruah
Rgenta Therapeutics, Woburn, MA, USA
4
Splitting the message: targeting leukaemia cells with split-mRNA lipid nanoparticles
Anouk Becker
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Melbourne, Australia
5
CircRNA-mRNA interactions in cancer
Manuel Beltran
Sapienza Università di Roma; IRCCS – Regina Elena National Cancer Institute, Translational Oncology Research Unit, Rome, Italy
6
Variant-specific Quantification of Therapeutic Targets
Raffaela Berger
Momentum Biotechnologies, Freising, Germany
7
Optimization of siRNAs for the selective targetting of point mutations
Sergio Bordel
Lithuanian University of Health Sciences, Kaunas, Lithuania
8
Structural Features of Alu RNA that Guide ADAR-Mediated Editing
Ivana Borovska
Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia
9
Multi-Omics Liquid Biopsy for Cancer Detection and Treatment-Response Prediction
Guy Brachya
Sharett Institute for Oncology, Hadassah Medical Center, Jerusalem, Israel
10
Cell-Free Chromatin Profiling as a Non-Invasive Predictor of Treatment Response in Head and Neck Cancer
Dorit Shemesh
Sharett Institute for Oncology, Hadassah Medical Center; Center of Computational Medicine, The Hebrew University of Jerusalem, Israel
11
Using selectively-expressed RNA-loaded nanoparticles to achieve Tph2-dependent BDNF overexpression in serotonergic neurons
Alex Brown
Leibniz Institute of Resilience Research gGmbH; Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, Germany
12
Casting Light on RNA Delivery: A NanoBRET based RNA Delivery Quantification Method utilizing Fluorescent Base Analogues
Jonas Burmester
Helsinki Institute of Life Science, University of Helsinki, Finland
13
AMCAP™: Effortless mRN Manufacturing by Next-Generation One-Pot Enzymatic Reaction
Massimo Carraro
Anemocyte s.r.l., Gerenzano VA, Italy
14
Coordinated regulation of Nuclear Envelope integrity and STING trafficking by miR-30d suppresses innate immunity in Breast Cancer
Suvarna Chatterjee
Cancer Cell Signalling Lab, ICGEB-International Centre for Genetic Engineering and Biotechnology; Department of Life Sciences, University of Trieste, Italy
15
Characterization of an RNA aptamer hampering CAF-cancer cells interplay in NSCLC
Giuseppe Ciccone
Institute of Endotypes in Oncology, Metabolism and Immunology (IEOMI), National Research Council (CNR), Naples, Italy
16
Advancing RNAi therapeutics: Integrating Strategies for Optimal Lead Identification and Effective Tissue Delivery
Pratik Dave
Roche Pharma Research & Early Development (pRED), Therapeutic Modalities,
Roche Innovation Center Basel, Switzerland
17
Correcting RNA dysregulation to reverse epitope loss and resistance to CD22-directed chemotherapy
Jacinta Davis
Division of Cancer Pathobiology, Children’s Hospital of Philadelphia, PA, USA
18
Sequence engineering to de-immunize mRNA to expand its therapeutic window
Manisha du Plessis
RiboPro, Oss, Netherlands
19
MicroRNAs shape early neural fate within a critical time window in human brain organoids
Lisa Emmenegger
Laboratory for Systems Biology of Gene Regulatory Elements, Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany
20
SECN-15: A neuropilin-1-targeting antisense oligonucleotide overcomes checkpoint inhibitor resistance through remodeling of the tumor microenvironment
Julia Festag
Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany
21
saRNA Immunisation Accelerates Antibody Discovery Against Challenging GPCR Targets
Fabio Fisher
AstraZeneca, Cambridge, UK
22
ASO-mediated modulation of HTT 3’UTR polyadenylation alters the level of huntingtin in human cell lines
Agnieszka Fiszer
Institute of Bioorganic Chemistry Polish Academy of Sciences, Poznan, Poland
24
Optimizing formulations for mRNA delivery into the muscle
Jonas Füner
preclinics discovery GmbH, Potsdam, Germany
25
Translational Constraints Control Poly-Dipeptide Repeat Expression and RNA Metabolism from C9ORF72-Derived GGGGCC Repeat Expansions
Keith Gagnon
Wake Forest University School of Medicine, Winston-Salem, NC, USA
26
7SK depletion preserves the somatic transcriptome but affects axonal RNA homeostasis in human iPSC-derived motoneurons
Gayatri Gandhi
Institute of Clinical Neurobiology, University Hospital Würzburg, Germany
27
RNAmotifs 2.0: A Framework for Inferring Multivalent RNAMotifs and their Candidate Regulators of Splicing
Mariachiara Grieco
Department of Oncology and Hemato-Oncology, University of Milan; Italian Institute for Genomic Medicine, c/o IRCCS, Candiolo (TO), Italy
28
Small molecules acting on RNA targets in cancer (SMART-C)
Benedetto Grimaldi
Istituto Italiano di Tecnologia – Center for Convergent Technologies, Genova, Italy
29
A new class of antisense oligonucleotides targeting regions downstream of genes directs mRNA for degradation and decreases gene expression
Pawel Grzechnik
University of Manchester, School of Biological Sciences, Manchester, UK
30
Nforce toolboox :Seamless product development to Tech adaption
Ashiqul Haque
Quantoom Biosciences, Nivelles, Belgium
31
RNAi for selective therapeutic immunity
Reka Haraszti
University Hospital Tübingen, Department of Medicine II, Gene and RNA Therapy Center Tübingen, Germany
32
Epitranscriptomic Signatures in Frontotemporal Dementia
Nina Hempel
German Center for Neurodegenerative Diseases, Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, Göttingen, Germany
33
When Oligonucleotide Drugs Clog the RNA Exosome: MS-Based Interactome Profiling Reveals a Novel Toxicity Mechanism
Daniel Hofacker
Interfaculty Institute of Biochemistry, University of Tübingen, Germany
34
Singapore Undiagnosed Research Endeavour (SUREKids): Investigating Splice-altering Genomic Variants in Pediatric Patients
Chaerish Eint Myet Chae Htoo
Department of Genomic Medicine, KK Women’s & Children’s Hospital, Singapore
35
Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition
Wenxin Hu
Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia
36
Identifying optimal untranslated regions (UTRs) for mRNA expression
Danai Kati
Nucleic Acid Therapeutics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
37
A pleiotropic pan-effective drug for cardiometabolic disease
Michael Khan
Argonaute RNA, Bristol, UK
38
Splicing misregulation leads to metabolic vulnerability: vitamin B12 as a candidate therapy for PUF60-related Verheij syndrome
Jonathan Kölschbach
Max Planck Institute for Biology of Ageing, Cologne, Germany
39
A direct interaction between MBNL and SFPQ drives alternative splicing regulation
Eliza Kopera
Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Poznan, Poland
40
Reduced RNA acetyltransferase NAT10 activity is associated with increased cellular stress in keratinocytes and enhanced inflammatory responses in mouse model of psoriasis
Pavel Kudrin
Institute of Biomedicine and Translational Medicine; Institute of Clinical Medicine, University of Tartu, Estonia
41
Adipose splicing plasticity in response to nutrient and inflammatory inputs
Esther Landaluce Iturriria
Center for Integrative Genomics, University of Lausanne, Switzerland
42
Transcriptomic analysis reveals downstream effectors of the oncogenic lncRNA EPCART in prostate cancer
Hana Hien Le
Tampereen Yliopisto Kaupin Kampus, Tampere, Finland
43
SurfaceScout™: A Chemoproteomic Platform for Comprehensive Profiling of Cell Surface Proteins and Macromolecular Uptake Mechanisms
Anika Kötemann
Momentum Biotechnologies, Freising, Germany
44
Understanding the Exon Target Space of Splicing Modifying Compounds
Felina Lenkeit
Novartis Biomedical Research, Basel, Switzerland
45
RBM15 as a Rheostat of RNA Fate: Context-Dependent m⁶A Wiring and Immune Evasion in Pancreatic Adenocarcinoma
Fengze Li
Queen Mary University of London, UK
46
Accelerating Hit-to-Lead Discovery for OligonucleotideTherapeutics Using an Integrated Platform
Xibo Li
Synoligo Biotechnologies, Morrisville, NC, USA
47
RNA-based cell fate reprogramming for cancer immunotherapy
Beatriz Lourenço Vaz
CNC – Centre for Neuroscience and Cell Biology; CiBB – Centre for Innovative Biomedicine and Biotechnology; PDBEB – Doctoral Programme in Experimental Biology and Biomedicine, Institute of Interdisciplinary Research, University of Coimbra, Portugal; Molecular Medicine and Gene Therapy, Lund Stem Cell Centre; Wallenberg Centre for Molecular Medicine, Lund University, Sweden
48
The influence of the HTT exon 1 nucleotide sequence on exon 1 splicing: Possible implications for Huntington’s disease
Camilla Maffezzini
Department of Biosciences, University of Milan, Istituto Nazionale di Genetica Molecolare, Milano, Italy
49
Decoding RNA 5′ Cap Diversity through Reverse Transcriptase Fingerprints
Flaminia Mancini
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague), Chemical Biology of Nucleic Acids; Charles University, Faculty of Science, Department of Cell Biology, Prague, Czech Republic
50
Embryonic Stem Cell-specific Phosphorylation Shapes Splicing During Differentiation
Suchismita Masanta
International Institute of Molecular Mechanisms and Machines, Polish Academy of Sciences, Warsaw, Poland
51
OverExpression of tRNA His rescues peripheral neuropathy caused by mutations in histidyl-tRNA synthetase
Maria Menafra
Molecular Neurobiology Laboratory, Donders Institute for Brain, Cognition and Behaviour and Faculty of Science, Radboud University, Nijmegen, Netherlands
52
A circRNA-based CellREADR platform for cell-type specific effector protein expression
Lena Morschhäuser
Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, Germany
53
Integrated Nuclear Interactomics and Phosphoproteomics Identify RNA-Binding Proteins as Functional Targets of NEK2 in triple negative breast cancer
Chiara Naro
Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart; GSTeP-Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, Rome, Italy
54
Exploring treatment response-associated transcript isoform usage in triple-negative breast cancer
Katarzyna Nowis
Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
55
Development of mRNA Therapy to support TIL-therapy
Maria Öberg
Gothenburg University, Sahlgrenska Academy, Institute of Clinical Sciences, Department of Surgery, Gothenburg, Sweden
56
NUDT2 at the Interface of RNA Decapping and Disease: Expression and Post-Transcriptional Regulation
Gibrán Pedraza-Vázquez
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague), Chemical Biology of Nucleic Acids, Prague,
Czech Republic
57
UTR optimization enhances antigen presentation and CD8⁺ T-cell immunity in mRNA cancer vaccines
Stefano Persano
Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy
58
Circular RNA-mediated alternative splicing in lung cancer: toward functional isoform restoration
Justyna Raczkowska
Laboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
59
An Integrated Discovery Platform for Accelerating Oligonucleotide Therapeutics via Advanced Conjugate Delivery Systems
Laura Reyes Fraile
WuXi Biology, WuXi AppTec, Shanghai, China
60
SOLiD-MaP: A Photoproximity Labeling Platform for Small Molecule Binding Site Mapping on RNA
Lin Rietveld
Division of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
61
Mitochondria-targeted catalytic RNAs for selective silencing of mutant transcripts in mitochondrial diseases
Katarzyna Rolle
Department of Molecular Neurooncology, Institute of Bioorganic Chemistry Polish Academy of Sciences, Poznan, Poland
62
An Integrated Antibody Discovery and LNP-mRNA Platform for Targeted Gene Delivery
Becky Sadler
VectorBuilder GmbH, Neu-Isenburg, Germany
63
Exploring Structural Dynamics of In Vitro Transcribed Therapeutic mRNAs with Atomic Force Microscopy
Afsheen Shahbaz
University of Kent, Canterbury, UK
64
Sequence-resolved hybridisation kinetics for RNA-guided target recognition
Archana Sivaraman
Kavli Institute of NanoScience, Delft University of Technology, Delft, The Netherlands
65
CRISPR-Cas9-based Strategy for Excision of the CGG Repeat Expansion from the FMR1 gene in Fragile X-linked conditions
Natalia Stepczak
Department of Gene Expression, Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Poznan, Poland
66
Exploring Synergistic Effects of Transient OSKM Factors and pro-proliferative miR-199a-3p using mRNA-LNP for Cardiac Regeneration
Yanie Tan
School of Cardiovascular and Metabolic Medicine & Sciences and British Heart Foundation Centre of Research Excellence; MRC/BHF Centre of Research Excellence in Advanced Cardiac Therapies (REACT), King’s College London, UK
67
Unsupervised co-clustering unveils metabolic pathway aberrations linked with patient prognosis in head and neck squamous cell carcinoma
Giulia Toti
Università degli studi di Foggia, Italy
68
Beyond Group-Level Transcriptomics: Patient-Level Aberrant Splicing Reveals Recurrent Patterns in Alzheimer’s Disease
Atakan Unlu
Gebze Technical University, Kocaeli, Türkiye
69
Ferritin-Polyamine Conjugates for Targeted and Enhanced Delivery of siRNA
Despoina Maria Varouhaki
Sapienza University of Rome, Italy
70
A Novel Approach for dsRNA Removal on Oligo dT with Acidic Denaturation
Nicolai Wagner
Sartorius BIA Separations d.o.o., Ajdovščina, Slovenia
71
RECKvar3 in Glioblastoma: Insights into Its Potential as a Prognostic Biomarker and Therapeutic Target
Sheila M B Winnischofer
Federal University of Paraná, Curitiba, Brazil
72
Exploring the role of long noncoding RNA in Retinitis Pigmentosa
Maria Zawadzka
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli; University of Campania “Luigi Vanvitelli”, Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (Distabif), Naples, Italy
73
Protein-coding Circular RNAs identified in Alzheimer’s Disease
Sulthan Rafi Ibrahim
The University of New South Wales (UNSW) Sydney, Kensington, Australia
74
Serum miRNAs as potential monitoring and prognostic biomarkers of muscle wasting progression in Myotonic Dystrophy type I.
Leonidas A Phylactou
The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
75
CRISPR Screen Identifies TOP3B as a Key Regulator in RNA Splicing
Shar-yin N. Huang
Laboratory of Molecular Pharmacology, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
76
Deoxyribonucleotide incorporation reshapes mRNA design beyond canonical ribonucleotide boundaries
Giovana Bavia Bampi
LMU University Hospital, LMU Medizin, Department of Pediatrics, Ludwig-Maximilians-Universität München, Germany
77
The UHMK1 kinase regulates splicing of DNA damage response genes in melanoma cells
Leticia Fröhlich Archangelo
Ribeirao Preto Medical
School – University of Sao Paulo (FMRP-USP), Ribeirao Preto, Brazil
